major breakthrough is on the horizon for Crohn's disease

December 1997

    A major breakthrough is on the horizon for Crohn's disease. The drug will be called infliximab (Avakine)...by Centocor.

    Crohn's is an autoimmune disease. Tumor necrosis factor (TNF) is involved. Avakine is a monoclonal antibody that blocks this factor...and slows the inflammation.

    In fact, it shows dramatic improvement in two-thirds of patients with moderate to severe Crohn's. One injection gives benefits lasting several months.

Get concise advice on drug therapy, plus unlimited access to CE

Pharmacist's Letter membership benefits include:

  • 12 issues every year — what you need to know and do, right now
  • Quick, practical reference charts and tools
  • Comprehensive CE library to meet license renewal and state requirements
  • Multiple course formats including live webinars, podcasts, and CE-in-the-Letter to match your learning style
  • Plus much more!

Choose the right tier for your needs today.

Already a subscriber? Log in

Volume pricing available. Get a quote